Payment overview · 2025
General Payments
$388.06
42 reported records · 2 companies
Healthcare provider profile · identity verified
Ki S Cho, M.D.
Allopathic & Osteopathic Physicians|Internal Medicine · SANTA CLARA, CA · NPI 1225122880
Verified facts
What the public records show
CMS Open Payments records show Ki S Cho, M.D. received $388.06 in general payments during 2025 across 42 reported records.
ABBVIE INC. accounted for 84.7% of that reported general-payment amount.
The Open Payments records used for this analysis explicitly named 3 associated products.
A separate comparison found the same explicitly named product in public Medicare Part D data: Creon, Zenpep.
ABBVIE INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported CREON as an associated drug or biological on 91561 records involving 20616 distinct recipient NPIs. Public Medicare Part D data also shows 118 claims for Creon by this doctor in 2024.
Aimmune Therapeutics, Inc. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported ZENPEP as an associated drug or biological on 32144 records involving 12432 distinct recipient NPIs. Public Medicare Part D data also shows 43 claims for Zenpep by this doctor in 2024.
These records do not establish that a payment influenced prescribing or medical care.
Separate record types
Research & Ownership
Research Payments (direct recipient): not present in the loaded data
Associated Research Funding (for example, named PI): not present in the loaded data
Ownership / Investment: not present in the loaded data
These categories are never added into the General Payments headline. Associated research funding must not be described as money the doctor personally received unless the source record supports that conclusion.
Who paid this doctor?
Companies in 2025 General Payments
| Reported company | Canonical company | Amount | Share | Records | Year |
|---|---|---|---|---|---|
| ABBVIE INC. | Unresolved — no canonical attribution shown | $328.49 | 84.7% | 39 | 2025 |
| Aimmune Therapeutics, Inc. | Unresolved — no canonical attribution shown | $59.57 | 15.3% | 3 | 2025 |
What were the payments for?
Payment categories
| Category | Amount | Records |
|---|---|---|
| Food and Beverage | $388.06 | 42 |
A meal, consulting fee, royalty, and travel payment describe different kinds of reported relationships and should not be interpreted as equivalent.
Analysis 1 · Payment-linked products
Products named in Open Payments records
| Reported product | Type | Reported company | Related amount* | Records | Year |
|---|---|---|---|---|---|
| CREON Normalized: creon |
Drug | ABBVIE INC. | $294.14 | 34 | 2025 |
Source payment records
|
|||||
| LINZESS Normalized: linzess |
Drug | ABBVIE INC. | $181.87 | 22 | 2025 |
Source payment records
|
|||||
| ZENPEP Normalized: zenpep |
Drug | Aimmune Therapeutics, Inc. | $59.57 | 3 | 2025 |
Source payment records
|
|||||
* Product-associated amounts are non-additive because one payment record may name more than one product.
These products were named on specific Open Payments records. A named product does not show that the payment influenced treatment or prescribing.
Public prescribing for products named in payments
| Open Payments product | Payment year | Part D brand | Part D year | Claims | Match method | Source |
|---|---|---|---|---|---|---|
| CREON creon |
2025 | Creon | 2024 | 118 | exact normalized | Medicare Part D |
| ZENPEP zenpep |
2025 | Zenpep | 2024 | 43 | exact normalized | Medicare Part D |
The presence of the same drug in both datasets does not show that a payment caused or influenced a prescription.
Analysis 2 · Same-company prescribing overlap
Drugs reported in other payments from the same company that also appear in Medicare Part D
This analysis is independent from products named on this doctor’s individual payment records. A row appears only when the exact Open Payments reporting entity paid this doctor, that same reporting entity reported the drug or biological on at least 10 loaded General Payment records involving at least 2 distinct recipient NPIs, and this doctor has the same non-generic brand in public Part D data. This does not mean the company owns or manufactures the drug.
| Paying company | Payment year | Drug reported by same entity | Open Payments evidence | Part D | Claims | Beneficiaries |
|---|---|---|---|---|---|---|
| ABBVIE INC. Exact reporting entity; no affiliate inference |
2025 | CREON open payments reported associated product |
CMS Open Payments — General Payments 91561 supporting records · 20616 recipient NPIs · example record 1201352608 |
Creon · 2024 Exact normalized brand match · 1 Part D row |
118 | 67 |
| Aimmune Therapeutics, Inc. Exact reporting entity; no affiliate inference |
2025 | ZENPEP open payments reported associated product |
CMS Open Payments — General Payments 32144 supporting records · 12432 recipient NPIs · example record 1249641927 |
Zenpep · 2024 Exact normalized brand match · 1 Part D row |
43 | 30 |
These facts do not show that a payment was for the drug, that the company owns or manufactures the drug, or that a payment caused or influenced prescribing.
Public Medicare Part D data
Provider-and-drug rows loaded for 2024
| Brand | Generic | Claims | Beneficiaries |
|---|---|---|---|
| Atorvastatin Calcium | Atorvastatin Calcium | 1425 | 466 |
| Losartan Potassium | Losartan Potassium | 658 | 203 |
| Metformin Hcl | Metformin Hcl | 636 | 205 |
| Omeprazole | Omeprazole | 488 | 196 |
| Amlodipine Besylate | Amlodipine Besylate | 383 | 129 |
| Donepezil Hcl | Donepezil Hcl | 283 | 118 |
| Metoprolol Tartrate | Metoprolol Tartrate | 252 | 80 |
| Gabapentin | Gabapentin | 221 | 88 |
| Finasteride | Finasteride | 207 | 75 |
| Tamsulosin Hcl | Tamsulosin Hcl | 202 | 75 |
| Isosorbide Mononitrate Er | Isosorbide Mononitrate | 200 | 74 |
| Hydrochlorothiazide | Hydrochlorothiazide | 199 | 66 |
| Acarbose | Acarbose | 181 | 63 |
| Rosuvastatin Calcium | Rosuvastatin Calcium | 176 | 56 |
| Azithromycin | Azithromycin | 174 | 128 |
| Levothyroxine Sodium | Levothyroxine Sodium | 165 | 50 |
| Nitroglycerin | Nitroglycerin | 154 | 109 |
| Triamcinolone Acetonide | Triamcinolone Acetonide | 144 | 94 |
| Pioglitazone Hcl | Pioglitazone Hcl | 142 | 52 |
| Famotidine | Famotidine | 132 | 57 |
| Amoxicillin-Clavulanate Potass | Amoxicillin/Potassium Clav | 128 | 91 |
| Clotrimazole-Betamethasone | Clotrimazole/Betamethasone Dip | 126 | 65 |
| Ciprofloxacin Hcl | Ciprofloxacin Hcl | 124 | 89 |
| Creon | Lipase/Protease/Amylase | 118 | 67 |
| Nifedipine Er | Nifedipine | 116 | 40 |
| Alendronate Sodium | Alendronate Sodium | 114 | 37 |
| Ibandronate Sodium | Ibandronate Sodium | 112 | 44 |
| Glipizide | Glipizide | 103 | 34 |
| Ursodiol | Ursodiol | 103 | 46 |
| Pantoprazole Sodium | Pantoprazole Sodium | 101 | 37 |
| Losartan-Hydrochlorothiazide | Losartan/Hydrochlorothiazide | 97 | 32 |
| Atenolol | Atenolol | 95 | 33 |
| Lisinopril | Lisinopril | 89 | 34 |
| Tramadol Hcl | Tramadol Hcl | 88 | 30 |
| Diclofenac Sodium | Diclofenac Sodium | 79 | 31 |
| Meloxicam | Meloxicam | 77 | 41 |
| Albuterol Sulfate Hfa | Albuterol Sulfate | 74 | 28 |
| Propranolol Hcl | Propranolol Hcl | 69 | 44 |
| Cephalexin | Cephalexin | 68 | 44 |
| Sulindac | Sulindac | 67 | 28 |
| Januvia | Sitagliptin Phosphate | 66 | 23 |
| Hydrocodone-Acetaminophen | Hydrocodone/Acetaminophen | 65 | suppressed |
| Memantine Hcl | Memantine Hcl | 65 | 21 |
| Montelukast Sodium | Montelukast Sodium | 63 | 25 |
| Terazosin Hcl | Terazosin Hcl | 63 | 20 |
| Meclizine Hcl | Meclizine Hcl | 60 | 39 |
| Metoprolol Succinate | Metoprolol Succinate | 60 | 23 |
| Paroxetine Hcl | Paroxetine Hcl | 60 | 24 |
| Cefdinir | Cefdinir | 59 | 43 |
| Furosemide | Furosemide | 57 | 18 |
| Celecoxib | Celecoxib | 55 | 25 |
| Mometasone Furoate | Mometasone Furoate | 55 | 35 |
| Quetiapine Fumarate | Quetiapine Fumarate | 55 | 20 |
| Levocetirizine Dihydrochloride | Levocetirizine Dihydrochloride | 53 | 21 |
| Oxycodone-Acetaminophen | Oxycodone Hcl/Acetaminophen | 53 | suppressed |
| Amitriptyline Hcl | Amitriptyline Hcl | 46 | 16 |
| Lansoprazole | Lansoprazole | 45 | 23 |
| Amoxicillin | Amoxicillin | 44 | 29 |
| Ibuprofen | Ibuprofen | 44 | 18 |
| Clopidogrel | Clopidogrel Bisulfate | 43 | 13 |
| Hydrocortisone | Hydrocortisone | 43 | 29 |
| Simvastatin | Simvastatin | 43 | 13 |
| Zenpep | Lipase/Protease/Amylase | 43 | 30 |
| Fluticasone Propionate | Fluticasone Propionate | 41 | 19 |
| Paxlovid | Nirmatrelvir/Ritonavir | 41 | 41 |
| Latanoprost | Latanoprost | 39 | 12 |
| Olmesartan Medoxomil | Olmesartan Medoxomil | 39 | suppressed |
| Carvedilol | Carvedilol | 37 | 12 |
| Valacyclovir | Valacyclovir Hcl | 36 | 22 |
| Allopurinol | Allopurinol | 34 | 11 |
| Potassium Chloride | Potassium Chloride | 34 | 12 |
| Eliquis | Apixaban | 33 | 11 |
| Digoxin | Digoxin | 32 | suppressed |
| Naproxen | Naproxen | 32 | 14 |
| Sulfamethoxazole-Trimethoprim | Sulfamethoxazole/Trimethoprim | 32 | 15 |
| Tobramycin-Dexamethasone | Tobramycin/Dexamethasone | 32 | 19 |
| Citalopram Hbr | Citalopram Hydrobromide | 31 | 15 |
| Oxybutynin Chloride | Oxybutynin Chloride | 31 | 11 |
| Ranolazine Er | Ranolazine | 31 | 12 |
| Pramipexole Dihydrochloride | Pramipexole Di-Hcl | 29 | 11 |
| Vascepa | Icosapent Ethyl | 29 | suppressed |
| Zolpidem Tartrate | Zolpidem Tartrate | 29 | suppressed |
| Prednisone | Prednisone | 28 | suppressed |
| Tenofovir Disoproxil Fumarate | Tenofovir Disoproxil Fumarate | 28 | suppressed |
| Olmesartan-Hydrochlorothiazide | Olmesartan/Hydrochlorothiazide | 27 | suppressed |
| Ozempic | Semaglutide | 27 | suppressed |
| Entecavir | Entecavir | 26 | suppressed |
| Temazepam | Temazepam | 26 | suppressed |
| Vemlidy | Tenofovir Alafenamide | 26 | suppressed |
| Metronidazole | Metronidazole | 25 | 18 |
| Spironolactone | Spironolactone | 25 | suppressed |
| Doxycycline Hyclate | Doxycycline Hyclate | 24 | 12 |
| Ketoconazole | Ketoconazole | 24 | 11 |
| Tradjenta | Linagliptin | 24 | suppressed |
| Pravastatin Sodium | Pravastatin Sodium | 23 | suppressed |
| Chlorhexidine Gluconate | Chlorhexidine Gluconate | 22 | suppressed |
| Glipizide Er | Glipizide | 22 | suppressed |
| Icosapent Ethyl | Icosapent Ethyl | 22 | suppressed |
| Repaglinide | Repaglinide | 22 | suppressed |
| Metformin Hcl Er | Metformin Hcl | 21 | suppressed |
| Sucralfate | Sucralfate | 21 | suppressed |
| Acetaminophen-Codeine | Acetaminophen With Codeine | 19 | suppressed |
| Alprazolam | Alprazolam | 19 | suppressed |
| Betamethasone Dipropionate | Betamethasone Dipropionate | 19 | suppressed |
| Procto-Med Hc | Hydrocortisone | 19 | suppressed |
| Clonazepam | Clonazepam | 18 | suppressed |
| Escitalopram Oxalate | Escitalopram Oxalate | 18 | suppressed |
| Glimepiride | Glimepiride | 18 | suppressed |
| Lisinopril-Hydrochlorothiazide | Lisinopril/Hydrochlorothiazide | 18 | suppressed |
| Benazepril Hcl | Benazepril Hcl | 17 | suppressed |
| Estradiol | Estradiol | 17 | suppressed |
| Hydroxyzine Hcl | Hydroxyzine Hcl | 17 | suppressed |
| Olanzapine | Olanzapine | 17 | suppressed |
| Sildenafil Citrate | Sildenafil Citrate | 17 | suppressed |
| Diphenoxylate-Atropine | Diphenoxylate Hcl/Atropine | 16 | suppressed |
| Omega-3 Acid Ethyl Esters | Omega-3 Acid Ethyl Esters | 16 | suppressed |
| Trazodone Hcl | Trazodone Hcl | 16 | suppressed |
| Divalproex Sodium | Divalproex Sodium | 15 | suppressed |
| Jardiance | Empagliflozin | 15 | suppressed |
| Lorazepam | Lorazepam | 15 | suppressed |
| Mupirocin | Mupirocin | 15 | suppressed |
| Sumatriptan Succinate | Sumatriptan Succinate | 15 | suppressed |
| Theophylline Er | Theophylline Anhydrous | 15 | suppressed |
| Esomeprazole Magnesium | Esomeprazole Magnesium | 14 | suppressed |
| Megestrol Acetate | Megestrol Acetate | 14 | suppressed |
| Tolterodine Tartrate Er | Tolterodine Tartrate | 14 | suppressed |
| Ventolin Hfa | Albuterol Sulfate | 14 | suppressed |
| Amiodarone Hcl | Amiodarone Hcl | 13 | suppressed |
| Ezetimibe | Ezetimibe | 13 | suppressed |
| Folic Acid | Folic Acid | 13 | suppressed |
| Ondansetron Odt | Ondansetron | 13 | suppressed |
| Tramadol Hcl-Acetaminophen | Tramadol Hcl/Acetaminophen | 13 | suppressed |
| Warfarin Sodium | Warfarin Sodium | 13 | suppressed |
| Wixela Inhub | Fluticasone Propion/Salmeterol | 13 | suppressed |
| Lantus Solostar | Insulin Glargine,hum.Rec.Anlog | 12 | suppressed |
| Raloxifene Hcl | Raloxifene Hcl | 12 | suppressed |
| Albuterol Sulfate | Albuterol Sulfate | 11 | suppressed |
| Fluocinonide | Fluocinonide | 11 | suppressed |
| Sertraline Hcl | Sertraline Hcl | 11 | suppressed |
| Triamterene-Hydrochlorothiazid | Triamterene/Hydrochlorothiazid | 11 | suppressed |
Timeline
Payment and prescribing data by year
Open Payments and Medicare Part D may refer to different years. They are shown separately rather than aligned as if they describe the same period.
| Year | General Payments | Main payer | Explicit products | Company overlaps | Part D coverage |
|---|---|---|---|---|---|
| 2025 | $388.06 · 42 records | ABBVIE INC. | CREON, LINZESS, ZENPEP | 2 | — |
| 2024 | — | — | — | — | Complete |
Questions to ask
Questions you could discuss with your doctor
- What role, if any, does Creon play in your treatment recommendations for me?
- How do you evaluate evidence when you have a financial relationship with ABBVIE INC.?
- Are there reasonable alternatives I should understand when we discuss treatment options?
- How should I interpret the industry-payment records shown here in the context of my care?
These are general questions generated from reviewed templates. They are not personalized medical advice.
Sources and limitations
How to read this page
- Payment and Medicare prescribing data can cover different years; every comparison shows both years explicitly.
- Part D does not represent a doctor’s entire practice; it excludes many patients and is subject to CMS public-release thresholds.
- Company–drug relationships must have an auditable source, a precise relationship type, and a valid evidence period. Unresolved mappings are not published.
- Generic drug claims are not attributed to a specific manufacturer without manufacturer-level evidence.
- When a source extract is incomplete, missing rows are never treated as proof of no payments or no prescriptions.
Loaded source releases
| Dataset | Year | Publication | Source |
|---|---|---|---|
| CMS Open Payments — General Payments | 2025 | 2026-06-30 | Original source |
| Medicare Part D Prescribers by Provider and Drug | 2024 | 2026-05-06 | Original source |
| NPPES Data Dissemination V2 | current / reference data | 2026-08-10 | Original source |
Full methodology · Questions & answers · Report a possible error